CL2009000731A1 - Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea. - Google Patents

Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.

Info

Publication number
CL2009000731A1
CL2009000731A1 CL2009000731A CL2009000731A CL2009000731A1 CL 2009000731 A1 CL2009000731 A1 CL 2009000731A1 CL 2009000731 A CL2009000731 A CL 2009000731A CL 2009000731 A CL2009000731 A CL 2009000731A CL 2009000731 A1 CL2009000731 A1 CL 2009000731A1
Authority
CL
Chile
Prior art keywords
receptor
orl
epilepsy
anxiety
alzheimer
Prior art date
Application number
CL2009000731A
Other languages
English (en)
Inventor
Saskia Dr Zemolka
Bert Dr Nolte
Sven Dr Frormann
Claudia Dr Hinze
Klaus Dr Linz
Werner Dr Englberger
Has Prof Dr Schickm
Helmut Dr Sonnenschein
Wolfgang Dr Schroder
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of CL2009000731A1 publication Critical patent/CL2009000731A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE FORMULA GENERAL 1, A1, A2, A3, A4, R1, R2, R3, R5, R6, W, X, Y1, Y1', Y2, Y2', Y3, Y3', Y4 E Y4', TODO DE ACUERDO A LO DEFINIDO EN LA MEMORIA DESCRIPTIVA QUE POSEEN AFINIDAD CON EL RECEPTOR DEOPLOIDES IJ Y CON EL RECEPTOR ORL-1, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS EN FORMA DE ESTEREOISÓMERO INDIVIDUAL O DE MEZCLA DE VARIOS DE LOS COMPUESTOS LIBRES Y/O DE SUS SALES FISIOLÓGICAMENTE COMPATIBLES Y/O SOLVATOS; Y SU USO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD, ESTRÉS, SINDROMES RELATIVOS AL ESTRÉS. DEPRESION, EPILEPSIA. ENFERMEDAD DE ALZHEIMER, DEMENCIA SENIL, ENTRE OTROS
CL2009000731A 2008-03-27 2009-03-25 Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea. CL2009000731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08005808 2008-03-27

Publications (1)

Publication Number Publication Date
CL2009000731A1 true CL2009000731A1 (es) 2009-05-15

Family

ID=39506563

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000731A CL2009000731A1 (es) 2008-03-27 2009-03-25 Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.

Country Status (28)

Country Link
US (1) US8293758B2 (es)
EP (1) EP2260042B1 (es)
JP (1) JP5597188B2 (es)
KR (1) KR101615505B1 (es)
CN (1) CN102046633B (es)
AR (1) AR071068A1 (es)
AT (1) ATE525379T1 (es)
AU (1) AU2009228647B2 (es)
BR (1) BRPI0910607A2 (es)
CA (1) CA2719742C (es)
CL (1) CL2009000731A1 (es)
CO (1) CO6251244A2 (es)
CY (1) CY1112095T1 (es)
DK (1) DK2260042T3 (es)
EC (1) ECSP11010529A (es)
ES (1) ES2371230T3 (es)
HR (1) HRP20110721T1 (es)
IL (1) IL208278A (es)
MX (1) MX2010009955A (es)
NZ (1) NZ587831A (es)
PE (1) PE20091650A1 (es)
PL (1) PL2260042T3 (es)
PT (1) PT2260042E (es)
RU (1) RU2497824C2 (es)
SI (1) SI2260042T1 (es)
TW (1) TWI450899B (es)
WO (1) WO2009118173A1 (es)
ZA (1) ZA201007645B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006033114A1 (de) * 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
TWI450900B (zh) 2008-03-24 2014-09-01 Medivation Technologies Inc 橋聯雜環化合物及使用方法
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
CL2009000731A1 (es) 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.
EP2260022B1 (de) 2008-03-27 2017-01-04 Grünenthal GmbH Substituierte cyclohexyldiamine
JP5542119B2 (ja) 2008-03-27 2014-07-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング スピロ（５．５）ウンデカン誘導体
KR20120075500A (ko) 2008-03-27 2012-07-06 그뤼넨탈 게엠베하 치환된 4-아미노사이클로헥산 유도체
AU2009228637B2 (en) 2008-03-27 2013-12-19 Grunenthal Gmbh (Hetero-)aryl cyclohexane derivatives
HRP20140650T1 (hr) 2008-03-27 2014-09-26 Grünenthal GmbH Hidroksimetilcikloheksilamini
CN102711466A (zh) 2009-09-23 2012-10-03 梅迪维新技术公司 桥连杂环化合物及其使用方法
WO2011038161A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
TWI582092B (zh) * 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
EP3459533A1 (en) * 2010-08-04 2019-03-27 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
PL2649044T3 (pl) * 2010-12-08 2018-02-28 Grünenthal GmbH Sposób syntezy podstawionych pochodnych aminocykloheksanonu
CA2829045A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
ME02754B (me) 2011-03-23 2018-01-20 Trevena Inc Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
BR112014014202A2 (pt) * 2011-12-12 2017-06-13 Gruenenthal Gmbh formas sólidas de cloridrato de (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-espiro-[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
ES2686326T3 (es) 2014-07-15 2018-10-17 Grünenthal GmbH Derivados de azaspiro(4,5)decano sustituidos
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
HK1254672A1 (zh) 2015-12-14 2019-07-26 Trevena Spv2 Llc 治疗痛觉过敏的方法
CN116284027B (zh) * 2023-01-10 2025-07-11 云南大学 一种多取代五环螺吲哚啉衍生物及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055203A (en) * 1964-09-16 1967-01-18 Ici Ltd -ß-carboline derivatives, a process for their manufacture, and compositions containing them
US4065573A (en) * 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
US4115589A (en) * 1977-05-17 1978-09-19 The Upjohn Company Compounds, compositions and method of use
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
CH643502A5 (de) * 1980-03-25 1984-06-15 Alusuisse Metalldose mit membranverschluss.
US4291039A (en) * 1980-08-08 1981-09-22 Miles Laboratories, Inc. Tetrahydro β-carbolines having anti-hypertensive activity
DE3309596A1 (de) * 1982-08-05 1984-04-05 Basf Ag, 6700 Ludwigshafen 2-substituierte 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-ss-carboline, ihre herstellung und verwendung als arzneimittel
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
US5631265A (en) * 1994-03-11 1997-05-20 Eli Lilly And Company 8-substituted tetrahydro-beta-carbolines
US5861409A (en) * 1995-05-19 1999-01-19 Eli Lilly And Company Tetrahydro-beta-carbolines
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
DE10123163A1 (de) 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
DE10135636A1 (de) 2001-07-17 2003-02-06 Gruenenthal Gmbh Substituierte 4-Aminocyclohexanole
EP1407092A1 (en) 2001-07-18 2004-04-14 Dipiemme Dies and Plastic Machinery S.r.l. A corrugated/undulated sheet having protuberances in the grooves defined by the corrugations; process and apparatus
DE10213051B4 (de) 2002-03-23 2013-03-07 Grünenthal GmbH Substituierte 4-Aminocyclohexanole
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252650A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Cyclohexyl-Harnstoff-Derivate
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
ATE457299T1 (de) 2002-11-12 2010-02-15 Gruenenthal Gmbh 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DE50306277D1 (de) * 2002-11-12 2007-02-22 Gruenenthal Gmbh 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
EP1633751A1 (en) * 2003-06-16 2006-03-15 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
US20070276030A1 (en) * 2003-08-14 2007-11-29 Wyeth Pyranobenzothiophene derivatives to treat infection with hepatitis c virus
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004023635A1 (de) 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023507A1 (de) 2004-05-10 2005-12-01 Grünenthal GmbH Substituierte Cyclohexylessigsäure-Derivate
DE102004023501A1 (de) 2004-05-10 2005-12-01 Grünenthal GmbH Oxosubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023506A1 (de) 2004-05-10 2005-12-01 Grünenthal GmbH Kettenverlängerte substituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023522A1 (de) 2004-05-10 2005-12-01 Grünenthal GmbH Substituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023508A1 (de) 2004-05-10 2005-12-08 Grünenthal GmbH Säurederivate substituierter Cyclohexyl-1,4-diamine
DE102004023632A1 (de) 2004-05-10 2005-12-08 Grünenthal GmbH Substituierte Cyclohexylcarbonsäure-Derivate
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1817025A2 (en) * 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
WO2007062175A2 (en) * 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
DE102005061429A1 (de) 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxazol-Derivate
DE102005061430A1 (de) 2005-12-22 2007-07-05 Grünenthal GmbH Substituierte Imidazolin-Derivate
DE102005061428A1 (de) 2005-12-22 2007-08-16 Grünenthal GmbH Substituierte Cyclohexylmethyl-Derivate
DE102005061427A1 (de) 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxadiazol-Derivate
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006033114A1 (de) 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
DE102006033109A1 (de) * 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009235A1 (de) 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009319A1 (de) * 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP5542119B2 (ja) 2008-03-27 2014-07-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング スピロ（５．５）ウンデカン誘導体
CL2009000731A1 (es) 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.
KR20120075500A (ko) 2008-03-27 2012-07-06 그뤼넨탈 게엠베하 치환된 4-아미노사이클로헥산 유도체
HRP20140650T1 (hr) 2008-03-27 2014-09-26 Grünenthal GmbH Hidroksimetilcikloheksilamini
AU2009228637B2 (en) 2008-03-27 2013-12-19 Grunenthal Gmbh (Hetero-)aryl cyclohexane derivatives
EP2260022B1 (de) 2008-03-27 2017-01-04 Grünenthal GmbH Substituierte cyclohexyldiamine

Also Published As

Publication number Publication date
EP2260042A1 (de) 2010-12-15
CY1112095T1 (el) 2015-11-04
TWI450899B (zh) 2014-09-01
ZA201007645B (en) 2011-08-31
AU2009228647A1 (en) 2009-10-01
MX2010009955A (es) 2010-09-30
SI2260042T1 (sl) 2011-11-30
HK1149759A1 (en) 2011-10-14
ES2371230T3 (es) 2011-12-28
PL2260042T3 (pl) 2012-02-29
DK2260042T3 (da) 2011-10-31
CO6251244A2 (es) 2011-02-21
IL208278A0 (en) 2010-12-30
EP2260042B1 (de) 2011-09-21
AU2009228647B2 (en) 2013-07-04
US20090247561A1 (en) 2009-10-01
AR071068A1 (es) 2010-05-26
TW200940541A (en) 2009-10-01
CA2719742C (en) 2016-11-08
RU2497824C2 (ru) 2013-11-10
KR101615505B1 (ko) 2016-04-26
US8293758B2 (en) 2012-10-23
IL208278A (en) 2014-06-30
PT2260042E (pt) 2011-12-06
WO2009118173A1 (de) 2009-10-01
NZ587831A (en) 2012-03-30
RU2010143437A (ru) 2012-05-10
HRP20110721T1 (hr) 2011-11-30
JP2011517670A (ja) 2011-06-16
JP5597188B2 (ja) 2014-10-01
CN102046633B (zh) 2015-03-25
PE20091650A1 (es) 2009-11-07
CN102046633A (zh) 2011-05-04
ATE525379T1 (de) 2011-10-15
BRPI0910607A2 (pt) 2015-09-22
KR20100132048A (ko) 2010-12-16
CA2719742A1 (en) 2009-10-01
ECSP11010529A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
CL2009000732A1 (es) Compuestos derivados de hidroximetil ciclohexilaminas sustituidos; composicion farmaceutica que contiene a dicho compuesto y sus uso como moduladores del receptor de opiodes u y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso del alcohol, hipertension, anorexia, obesidad y diarrea.
PE20221628A1 (es) Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CL2009000735A1 (es) Compuestos derivados de 1,4 di-amino-ciclohexil sustituido, moduladores del receptor de opioides y el receptor orl-1; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento del dolor, estados de ansiedad, depresion, epilepsia, disfuncion sexual, enfermedades cardiovasculares.
CL2008003787A1 (es) Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
NI201200044A (es) Compuestos de dióxido de iminotiadiazina como inhibodores de bace , composiciones y su uso
PA8779901A1 (es) Compuestos amino-heterocíclicos
PE20141120A1 (es) Compuestos heterociclicos
ATE478850T1 (de) Herstellung von eslicarbazepin und verwandten verbindungen mittels asymmetrischer hydrierung
CL2007000396A1 (es) Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos.
UY29827A1 (es) 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
DOP2004000876A (es) Compuestos de 4 fenil piperidina y sus usos como moduladores de los receptores opioides
BRPI0809579A8 (pt) formas cristalinas e seus usos
UY30399A1 (es) Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen"
CL2008003085A1 (es) Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
PE20091650A1 (es) Derivados de ciclohexano espirociclicos sustituidos
CL2009000733A1 (es) Compuestos derivados de (hetero) aril-ciclohexano sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, demencia senil, sintomas de abstinencia, abuso de alcohol.
AR058151A1 (es) Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina
DE502007002185D1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen